Anti-cyclic citrullinated peptide antibodies and paraoxonase-1 polymorphism in rheumatoid arthritis

BMC Musculoskeletal Disorders

Asif Jiman-Fatani¹  Hassan El-Banna¹ 

[1] Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia

关键词: Arylesterase;    Rheumatoid factor;    Paraoxonase-1 polymorphism;    Anti-CCP-2 antibodies;    Rheumatoid arthritis;   

Others  :  1091932
DOI  :  10.1186/1471-2474-15-379

 received in 2013-08-29, accepted in 2014-11-05,  发布年份 2014

【 摘 要 】

Background

Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease, with a worldwide prevalence of 0.5% to 1%. Anti-cyclic citrullinated peptide antibody (anti-CCP-2 Ab) is a marker of choice for diagnosing early and late RA. Anti-oxidant enzymes activity decreases in RA patients. Till now, the relationship between the rheumatoid factor (RF) and anti-CCP-2 Ab, anti-oxidant activity and polymorphism of paraoxenase-1 (PON-1) 192 Q/R in patients with RA has not been investigated. In this study, we aimed to determine the serum level of RF and anti-CCP-2 Ab, PON-1 activity and 192 Q/R polymorphism and arylesterase (ARE) activity in patients with RA. Also, we studied RA markers in different genotypes of PON-1 of RA patients.

Methods

A total of 120 RA patients and 90 healthy persons were subjected to full clinical examinations and routine laboratory tests. PON-1 and ARE activities were determined using an enzymatic spectrophotometric method. PON-1 192 gene polymorphism was determined using polymerase chain reaction based restriction fragment analysis. RF was measured by immunoturbidimetry method and anti-CCP-2 Ab was assayed by enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using SPSS for windows 20.0.

Results

The sensitivity and specificity of anti-CCP-2 Ab for the diagnosis of RA were 76.2% and 100% respectively. PON-1 and ARE activities were statistically lower (P <0.001) in the RA group compared to the control group. A negative correlation between RF and anti-CCP-2 Ab levels and PON-1 and ARE activities was found. No significant difference in the genotype distribution between RA patients and healthy persons was detected. RF and anti-CCP-2 Ab levels were higher in RA patients carried RR genotype than in those carried QQ genotype.

Conclusion

High RF and anti-CCP-2 antibody serum levels were found to be associated with decreased PON-1 and ARE activities with no correlation between PON-1 polymorphism and serum levels of RF and anti-CCP-2 Ab in patients with RA. These results may indicate an implication between antioxidant enzymes activity and serum levels of RF and anti-CCP-2 Ab.

【 授权许可】

   
2014 El-Banna and Jiman-Fatani; licensee BioMed Central Ltd.

【 参考文献 】

• [1]van Venrooij WJ, van Beers JJ, Pruijn GJ: Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 2008, 1143:268-285.
• [2]van Venrooij WJ, Zendman AJW, Pruijn GJM: Autoantibodies to citrullinated antigens in early rheumatoid arthritis. Autoimmun Rev 2006, 6:37-41.
• [3]Bauerová K, Bezek A: Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gene Physiol Biophys 1999, 18:15-20.
• [4]Gutteridge JM: Free radicals in disease processes: a complication of cause and consequence. Free Radical Res Commun 1993, 19:141-158.
• [5]Gambhir JK, Lali P, Jain AK: Correlation between blood antioxidant levels and lipid peroxidation in rheumatoid arthritis. Clin Biochem 1997, 30:351-355.
• [6]Halliwell B: Free radicals, antioxidants and human diseases: curiosity, cause or consequence. Lancet 1994, 344:721-724.
• [7]Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996, 7:69-76.
• [8]La Du BN: Structural and functional diversity of paraoxonases. Nat Med 1996, 2:1186-1187.
• [9]Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN: Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998, 101:1581-1590.
• [10]Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M: Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000, 101:2510-2517.
• [11]Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998, 423:57-60.
• [12]Eckerson HW, Wyte CM, La Du BN: The human serum paraoxonase/arylesterase polymorphism. Identification of phenotypes by their response to salts. Am J Hum Genet 1983, 35:214-227.
• [13]Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, Durrington PN: Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991, 86:193-199.
• [14]Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I: Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005, 46:7351-7354.
• [15]Miller SA, Dykes DD, Polesky HS: Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1998, 16:1215.
• [16]Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE: The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993, 3:73-76.
• [17]Adkins S, Gan KN, Mody M, La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993, 52:598-608.
• [18]Mansour HE, Metwaly KM, Hassan IA, Elshamy HA, Elbeblawy MM: Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection. Clin Med Insights Arthritis Musculoskelet Disord 2010, 3:33-42.
• [19]Kim HH, Kim J, Park SH, Kim SK, Kim OD, Choe JY: Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients. Korean J Intern Med 2010, 2:201-206.
• [20]Choi SW, Lim MK, Shin DH, ParK II, Shim SC: Diagnostic performances of anti-cyclic citrullinated peptides antibody and antifilaggrin antibody in Korean patients with rheumatoid arthritis. J Korean Med Sci 2005, 20:473-478.
• [21]Greiner A, Plischke H, Keliner H, Gruber R: Association of anti cyclic-citrullinated peptide antibodies, anti-citrullin antibodies, and 1gM and lgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci 2005, 1050:295-303.
• [22]Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P, Filippini M, Tampoia M, Afeltra A, Sebastiani G, Alpini C, Bini V, Bistoni O, Alunno A, Gerli R: Anticyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther 2013, 15(1):R16. BioMed Central Full Text
• [23]Al-Shukaili A, Al-Ghafri S, Al-Marhoobi S, Alkaabi J: Evaluation of anti mutated citrullinated vimentin antibodies, anticyclic citrullinated Peptide antibodies and rheumatoid factor in Omani patients with rheumatoid arthritis. Int J Rheumatol 2010, 12:2-7. R36
• [24]Dubucquoi S, Solau-Gervais E, Leftanc D, Marguerie L, Sibilia J, Goetz J: Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004, 63:415-419.
• [25]Lee DM, Schur PH: Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003, 62:870-874.
• [26]Berrocal B, Gonzalez C, Perez M, Navajo JA, Moreta I, Dávila C, Gonzalez Buitrago JM: Anti-cyclic citrullinated peptide autoantibody in 1gM RF positive patients. Clin Chim Acta 2005, 354:123-130.
• [27]Nielen MMJ, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, Dijkmans BAC, Hamann DO: Antibodies to citrullinated human fibrinogen have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204.
• [28]Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H: Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003, 48:2741-2749.
• [29]Bas S, Perneger TV, Kunzle E, Vischer TL: Comparative study of different enzyme immunoassays for measurement of 1gM and IgA rheumatoid factors. Ann Rheum Dis 2002, 61:505-510.
• [30]Safi MA, Houssien DA, David L, Scott DL: Disease activity and anti-cyclic citrullinated peptide (Anti-CCP) antibody in Saudi RF-negative rheumatoid arthritis patients. JKAU Med Sci 2012, 19:3-10.
• [31]Korkmaz C, Us T, Kaşifoğlu T, Akgün Y: Anti-cyclic citrullinated peptide (CCP) antibodies in patients with longstanding rheumatoid arthritis and their relationship with extra articular manifestations. Clin Biochem 2006, 39:961-966.
• [32]Altinadg O, Karakoc M, Soran N, Celik H, Celik N, Selek F: Paraoxonase and arylesterase activities in patients with rheumatoid arthritis. Rheumatism 2007, 22:132-136.
• [33]Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, Muhtaroglu S: Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 2005, 38:951-955.
• [34]Isik A, Koca SS, Ustundag B, Celik H, Yildirim A: Paraoxonase and arylesterase levels in rheumatoid arthritis. Clin Rheumatol 2006, 26:342-348.
• [35]Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K, Hashimoto K: Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci 2003, 72:2877-2885.
• [36]Nakamura K, Endo H, Kashiwazaki S: Serum oxidation activities and rheumatoid arthritis. Int J Tissue React 1987, 9:307-316.
• [37]Ediz L, Hiz O, Ozkol H, Gulcu E, Toprak M, Ceylan MF: Relationship between anti-CCP antibodies and oxidant and anti-oxidant activity in patients with rheumatoid arthritis. Int J Med Sci 2011, 8:139-147.
• [38]Kageyama Y, Takahashi M, Nagafusa T, Torikai E, Nagano A: Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 2008, 28:245-251.
• [39]Atzeni F, Sarzi-Puttini P, Dell’ Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL: Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006, 8:R3. BioMed Central Full Text
• [40]Hashemi M, Moazeni-Roodi AK, Fazaeli A, Sandoughi M, Bardestani GR, Kordi-Tamandani DM, Ghavami S: Lack of association between paraoxonase-1 Q192R polymorphism and rheumatoid arthritis in southeast Iran. Genet Mol Res 2010, 9:333-339.
• [41]Tripi LM, Manzi S, Chen Q, Kenney M, Shaw P, Kao A, Bontempo F, Kammerer C, Kamboh MI: Relationship of serum paraoxonase 1 activity and paraoxonase 1 genotype to risk of systemic lupus erythematosus. Arthritis Rheum 2006, 54:1928-1939.